---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-280125"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:29:58.346828+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal

## Summary
- Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.
- Tiered royalties increased to mid-single-digit to 20% on net sales; some development milestones reduced.
- Exclusive license option for olinciguat granted to entity controlled by CVCO Therapeutics; grantee pays IP costs.
- Proceeds will fund CNS pipeline build; company plans to raise capital as needed to support product plans.
- Olinciguat option, if exercised, would complete monetization of Cyclerion's historical sGC stimulator portfolio.

## SEC filing metadata
- accession: 0001193125-24-280125
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000119312524280125/0001193125-24-280125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000119312524280125/d856941d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-280125
- JSON: https://secwatch.observer/filing/0001193125-24-280125.json
- Plain text: https://secwatch.observer/filing/0001193125-24-280125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.